Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-Induced Peripheral Neuropathy Clinical Trial

Official title:

A Randomized Phase II Study Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03812523
• Other study ID #: SA2018005 LVD
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 2019
• Est. completion date: October 2021

Study information

• Verified date: April 2019
• Source: Southeastern Regional Medical Center
• Contact: Nathan Neufeld, DO
• Phone: 770-400-6035
• Email: nathan.neufeld[@]ctca-hope.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Randomized Phase II study Comparing Lorcaserin versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin

Description:

To examine lorcaserin a selective R-HT2c receptor antagonist approved by FDA as weight loss drug- for its ability to improve proprioceptive movements in patients with advanced colorectal cancer who developed neurotoxicity during oxaliplatin-based chemotherapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: October 2021
• Est. primary completion date: February 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject has a diagnosis of invasive colorectal cancer, locally advanced or advanced, requiring oxaliplatin-based chemotherapy for treatment.

• Subject has agreed to receive treatment at Cancer Treatment Centers of America, Southeastern Regional Medical Center.

• Subject is Male or Female

• Subject is 18 years of age or older.

• Subject is a patient who reports neurotoxicity symptom grade 2 or more according CTCAE criteria to his or her medical oncologist following one or more cycles of oxaliplatin-based chemotherapy treatment.

• Subject is a patient who is capable and accepting of completing study questionnaires at each data collection point.

• Subject has adequate English fluency for completion of data collection. The surveys were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the surveys.

• Subject must have the ability to understand and the willingness to sign a written informed consent

• Subject must be willing to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria:

• Subjects who have previously been exposed to neurotoxic agents including pyridoxine (>100 mg/day), colchicine, allopurinol, or phenytoin;

• Subjects with pre-existing comorbidities, such as: diabetes, uremia, significant peripheral vascular disease, HIV, or progressive or degenerative neurologic disorders (e.g., multiple sclerosis, B12 deficiency); cardiovascular valve disease, history of cardiovascular event,

• Subjects with a history of lumbosacral laminectomy or radiculopathy;

• Subjects who have been prescribed and taken gabapentin, pregabalin, or duloxetine currently or within the last 1 months)

• Subjects who have established or suspected family history of inherited neuropathy.

• Subjects unable to swallow indicated medication

• Subjects in general with a medical condition, laboratory finding, or physical exam finding that precludes participation

• Subject weight of =350 lbs.

• Subjects who currently use disallowed concomitant medications

• Subjects with any form of cardiac implants

• Subjects who report recent febrile illness that precludes or delays participation

• Subjects with pregnancy or lactation

• Subjects with known allergic reactions to components of the study product(s)

• Subjects receiving treatment with another investigational drug or other intervention

• Subjects with a history of or current tobacco or illegal substance use

• Subjects exhibiting significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation.

Related Conditions & MeSH terms

• Chemotherapy-Induced Peripheral Neuropathy
• Peripheral Nervous System Diseases

Intervention

Drug:
• Duloxetine 60 mg qd
60 mg tablet Taken by mouth, Once Daily for 180 Days
• Lorcaserin
10 mg tablet Taken by mouth Twice Daily for 180 Days

Locations

Country	Name	City	State
United States	Cancer Treatment Centers of America - Atlanta	Newnan	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Southeastern Regional Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment with respect to duloxetine of the effect of lorcaserin on the Pain Numerical Rating Scale.	Duloxetine efficacy as Measured by Pain Score 0-10 Numerical Rating Scale. Subject will rate level of pain experienced from 0 (No Pain) to 10 (Worst Possible Pain) for each question on the Brief Pain Inventory Short Form. A rating of 5 would be Moderate Pain.	180 days
Primary	Assessment with respect to duloxetine of the effect of lorcaserin on the patient-reported quality of life.	Subject quality of life will be measured using the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group-Neurotoxocity (FACT/GOG-NTX) Questionnaire. For each statement, the subject will answer 0-5 with 0 being "Not at All" and 5 being "Very Much"	180 days
Primary	Assessment with respect to duloxetine of the effect of lorcaserin on the patient-reported quality of life.	Subject quality of life will also be measured using the MD Anderson Symptom Inventory (MDASI) Questionnaire, with CTCA addendum. For each statement, the subject will answer from 0-10, with 0 being "Not Present" and 10 being "As Bad as You Can Imagine)	180 days